Aditx Therapeutics Inc. (NASDAQ: ADTX) stock gains by 4% during the current market trading session. Aditxt is working on technologies aimed at enhancing the immune system’s health through immunological surveillance and reprogramming. The immune monitoring technology developed by Aditxt is intended to offer a thorough profile of the immune system that is tailored to the individual.
>> 7 Top Picks for the Post-Pandemic Economy <<
What is happening?
AditxtScore for COVID-19 has been enhanced, according to Aditx. AditxtScore for COVID-19 is a multi-dimensional immune response test that detects multiple combinations of antibody responses against many specific antigens, has been improved to include a high-sensitivity neutralizing antibody diagnostic, allowing doctors to evaluate a person’s immune system response to the SARS-CoV-2 virus.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
Read More
AditxtScore for COVID-19, which was initially released in August of 2020, differs from standard antibody tests in that it provides a comprehensive picture of a persons’ immune response to numerous antigens linked to the SARS-CoV-2 virus. This multi-multiplex technique to collecting the complete range of SARS-CoV-2 biomarkers in a single test cycle provides a very comprehensive image of an individual’s immune response. AditxtScore for COVID-19 now incorporates the ability to detect neutralizing antibodies, which are a subset of virus-specific antibodies that prevent infection by dealing with viral particle entrance into cells.
Amro Albanna, Co-founder and Chief Executive Officer of Aditxt stated,
Every person’s immunological response is unique to them. Individual immunological responses to COVID-19 and COVID-19 vaccination have been studied, and they have discovered that the immediacy, intensity, and durability of antibody responses can vary greatly depending on a variety of factors. This new AditxtScore for COVID-19 gathers crucial information on how efficient an individual’s antibodies are in inactivating the virus. They think that when more people are vaccinated or infected with the virus, AditxtScore for COVID-19 with neutralizing antibody diagnostics will provide more comprehensive information about the quality of the immune response to the virus.
